Bicyclo Ring System Which Is Indole (including Hydrogenated) Patents (Class 546/201)
-
Publication number: 20040077851Abstract: Disclosed are cannabimimetic aminoalkylindole compounds and methos for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoinds. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual and to treat a condition in an animal or individual.Type: ApplicationFiled: July 25, 2003Publication date: April 22, 2004Inventors: Alexandros Makriyannis, Hongfeng Deng
-
Publication number: 20040072844Abstract: The present invention provides a compound of the formula: 1Type: ApplicationFiled: September 16, 2003Publication date: April 15, 2004Applicant: Roche Palo Alto LLCInventors: Ann Marie Madera, Robert James Weikert
-
Publication number: 20040067931Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.Type: ApplicationFiled: April 3, 2003Publication date: April 8, 2004Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
-
Publication number: 20040067939Abstract: The present invention provides glucokinase activators of formula I: 1Type: ApplicationFiled: September 30, 2003Publication date: April 8, 2004Inventor: Wendy Lea Corbett
-
Patent number: 6716840Abstract: Compounds having the general structure I are provided: X and Y are independently selected from the group consisting of CH2, N, NR9, C═O, C═S, S═O, SO2, S, O, (CR6R7)n, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of and L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r”) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.Type: GrantFiled: April 8, 2002Date of Patent: April 6, 2004Assignee: Chiron CorporationInventors: Daniel Chu, Rustum S. Boyce, David Duhl, Bryan H. Chang
-
Publication number: 20040063744Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS.Type: ApplicationFiled: April 29, 2003Publication date: April 1, 2004Inventors: Tao Wang, John F. Kadow, Nicholas A. Meanwell, Kap-Sun Yeung, Zhongxing Zhang, Zhiwei Yin, Zhilei Qiu, Daniel H. Deon, Clint A. James, Edward H. Ruediger, Carol Bachand
-
Publication number: 20040063724Abstract: The present invention provides a compound of the formula: 1Type: ApplicationFiled: September 16, 2003Publication date: April 1, 2004Applicant: Roche Palo Alto LLCInventors: Ann Marie Madera, Robert James Weikert
-
Publication number: 20040063939Abstract: The invention relates to a process for preparing hydroxyindolylglyoxylamides in high yields and particularly pure form.Type: ApplicationFiled: July 31, 2003Publication date: April 1, 2004Inventors: Hans-Joachim Jansch, Helge Hartenhauer, Hans Stange, Norbert Hofgen, Jurgen Schafer
-
Publication number: 20040043995Abstract: The invention relates to a compound of formula 1Type: ApplicationFiled: December 12, 2002Publication date: March 4, 2004Inventors: Eric Bignon, Jean Pierre Bras, Paul De Cointet, Pierre Despeyroux, Daniel Frehel, Danielle Gully
-
Patent number: 6699883Abstract: The present invention relates to 3-pyrroloimidazole derivatives of the general formula (I) wherein the imidazole radical is an optionally substituted imidazole ring, X, Y, A and B are, each independently of the others, carbon or nitrogen atoms, the radicals Z denote, each independently of the others, a hydrogen atom, a halogen atom, a pseudohalogen, an optionally substituted alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloaralkyl, cycloaralkenyl, cycloaralkynyl, aryl or alkoxy radical or an optionally substituted ring, to which one or two further, optionally substituted rings may be fused, and/or at least two of the radicals Z may be part of an optionally substituted ring, to which one or two further, optionally substituted rings may be fused, and to pharmaceutical compositions comprising at least one of the above-mentioned compounds, optionally in combination with carriers and/or adjuvants and/or excipients customary per se.Type: GrantFiled: April 4, 2002Date of Patent: March 2, 2004Assignee: Morphochem AGInventors: Alexander Doemling, Barbara Beck
-
Patent number: 6699864Abstract: The present invention provides compounds of the formula: wherein R1-R8, X, Y, Z, n and m are defined in the application. The compounds of the invention have affinity for the 5-HT1A receptor.Type: GrantFiled: June 20, 2002Date of Patent: March 2, 2004Assignee: H. Lundbeck A/SInventors: Thomas Ruhland, Christian Krog-Jensen, Mario Rottländer, Gitte Mikkelsen, Ejner Knud Moltzen, Kim Andersen
-
Patent number: 6699863Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.Type: GrantFiled: November 27, 2002Date of Patent: March 2, 2004Assignee: Allergan, Inc.Inventors: Steven W. Andrews, Jonathan J. Hebert
-
Publication number: 20040038986Abstract: Novel carbamate derivatives which are useful as drugs because of inhibiting activated blood coagulation factor X and thus exerting an anticoagulant effect.Type: ApplicationFiled: May 6, 2003Publication date: February 26, 2004Inventors: Fumio Itoh, Hiroshi Banno, Masaki Kawamura, Shuji Kitamura
-
Patent number: 6696469Abstract: Compounds of formula (I): wherein: X represents a heterocycle bonded to the remainder of the molecule by a nitrogen atom of the heterocycle, or an —NR2R3 group wherein R2 represents hydrogen or alkyl, and R3 represents aryl, 1,3 dihydro-2H-benzimidazolyl-2-one or alkyl substituted by a heterocycle, n represents zero or 1, R1 represents hydrogen or alkyl, Ra represents a single bond or an alkylene chain, A represents nitrogen or CH, E represents nitrogen or CRe, wherein Re is as defined in the description, Rb represents a single bond or an alkylene chain as defined in the description, W represents aryl or heteroaryl, Their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful for treatment of diseases or pathological conditions in which endothelial dysfunction is known.Type: GrantFiled: October 12, 2001Date of Patent: February 24, 2004Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Jean-Paul Vilaine, Nicole Villeneuve, Catherine Thollon, Marie-Pierre Bourguignon, Christophe Poitevin
-
Publication number: 20040029858Abstract: 2-(III-Indol-3-yl)-2-oxo-acetamide derivatives of formula (I) having antitumor activity in particular against solid tumors, specifically colon and lung tumors.Type: ApplicationFiled: July 10, 2003Publication date: February 12, 2004Inventors: Ernesto Menta, Nicoletta Pescalli
-
Patent number: 6689792Abstract: Compounds of formula (1) are provided: wherein R1 and R2 are H, OH, F, Cl, Br, I, 1 to 6 carbon alkyl or alkenyl, 1 to 6 carbon alkoxy, aryl, OR5, nitro, amino, CF3 or R1 and R2 are taken together to form a fused ring at the 2,3- or 3,4-positions providing a fused phenyl group or a benzodioxane group, or a 4- or 7-substituted indole group, or a 5- or 8-substituted quinoline group; R3 represents a group selected from hydrogen, a 1 to 6 carbon alkyl, a 1 to 4 carbon alkoxy or a halogen; R4 represents a group selected from hydrogen, 1 to 6 carbon alkyl or R5; R5 is CH2Ph in which the phenyl ring can be optionally substituted by a group selected from OMe, halogen, CF3; X is selected from a group represented by C, CR4, [[CHR4]] and CHCH2; A is selected from a group represented by N, NH, CH and CH2; B is selected from a group represented by ═O, ═S, H and H2; or A and B may be concatenated together to form indole, benzimidazole, indolone or indoline moieties; oType: GrantFiled: October 12, 2001Date of Patent: February 10, 2004Assignee: WyethInventors: Michael G. Kelly, Young H. Kang
-
Publication number: 20040024023Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.Type: ApplicationFiled: July 17, 2003Publication date: February 5, 2004Applicant: WyethInventors: Ronald Charles Bernotas, Steven Edward Lenicek
-
Publication number: 20040024190Abstract: An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: 1Type: ApplicationFiled: July 18, 2002Publication date: February 5, 2004Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Pierre Louis Beaulieu, Gulrez Fazal, Sylvie Goulet, George Kukolj, Martin Poirier, Youla S. Tsantrizos, Eric Jolicoeur, James Gillard, Marc-Andre Poupart, Jean Rancourt
-
Patent number: 6686362Abstract: Compounds of formula (I) in which R1, R2, R3 and R4 have the meanings given in the specification, are receptor tyrosine kinase inhibitors useful in the treatment of proliferative disorders, such as cancer.Type: GrantFiled: December 20, 2002Date of Patent: February 3, 2004Assignee: Theravance, Inc.Inventors: John H. Griffin, Roger Briesewitz, Jonathan W. Wray
-
Patent number: 6683074Abstract: This invention relates to certain cyclic amine derivatives of Formula (I) that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.Type: GrantFiled: September 26, 2001Date of Patent: January 27, 2004Assignee: Syntex (U.S.A.) LLCInventors: Leyi Gong, Denis John Kertesz, David Bernard Smith, Francisco Xavier Talamas, Robert Stephen Wilhelm
-
Patent number: 6683096Abstract: Indolylpiperidine compounds of formula (I) wherein: A1 represents an alkylene, alkyleneoxy, alkylenethio, alkanoyl or hydroxyalkylene group; A2 represents a single bond, an alkylene or alkenylene group; W represents a single bond or a phenylene or furanylene group which is unsubstituted or substituted by one or more halogen atoms, alkoxy groups and/or alkyl groups; R2 represents a hydrogen or halogen atom or an alkyl or alkoxy group; and R3 represents a carboxyl group or a tetrazolyl group. The present invention provides novel indolylpiperidine compounds having imporved antihistamine and antiallergic activity.Type: GrantFiled: December 4, 2001Date of Patent: January 27, 2004Assignee: Almirall Prodesfarma, S.A.Inventors: Lluis Pages Santacana, Silvia Fonquerna Pou, Carles Puig Duran, Maria Dolors Fernandez Forner
-
Publication number: 20040010014Abstract: This invention is directed towards novel compounds as opioid receptor modulators, antagonists, and agonists useful for the treatment of opioid modulated disorders such as pain and gastrointestinal disorders.Type: ApplicationFiled: March 26, 2003Publication date: January 15, 2004Inventors: Henry J. Breslin, Wei He, Robert W. Kavash
-
Publication number: 20040010012Abstract: A compound of formula (I), or a salt thereof, or a solvate thereof, wherein Ra represents a group R5 which is hydrogen, alkyl or optionally substituted aryl and Rb represents a moiety of formula (a), wherein X represents a hydroxy or an alkoxy group wherein the alkyl group may be substitued or unsubstituted or X represents a group NRsRt wherein Rs and Rt each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or Rs and Rt together with the nitrogen to which they arm attached form a heterocyclic group; R1 represents an alkyl or a substituted or unsubstituted aryl group; and R2, R3 and R4 each independently represent hydrogen, alkyl, aryl or substituted aryl; R6 and R7 each independently represent hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dialType: ApplicationFiled: November 20, 2002Publication date: January 15, 2004Applicant: SmithKline Beecham SpAInventors: Carlo Farina, Stefania Gagliardi, Guy Marguerite Marie Gerard Nadler
-
Patent number: 6677354Abstract: Disclosed are compounds of formula (I): wherein: Y represents a group (CH2)n, wherein n represents 0, 1 or 2; R1 is phenyl, naphthyl, a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; or a group NR3R4 wherein one of R3 and R4 is hydrogen or optionally substituted (C1-4)alkyl and the other is phenyl, naphthyl or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S, or R3 and R4 together with the N atom to which they are attached form a 5 to 7-membered cyclic amine which has an optionally fused phenyl ring; any of which R1 groups may be optionally substituted; R2 represents phenyl or a 5- or 6-membered heteroaryl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl group is substituted by R5, and further optional substituents; or R2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, OType: GrantFiled: December 16, 2002Date of Patent: January 13, 2004Assignee: SmithKline Beecham p.l.c.Inventors: Clive Leslie Branch, Christopher Norbert Johnson, Geoffrey Stemp, Kevin Thewlis
-
Publication number: 20040006229Abstract: The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.Type: ApplicationFiled: September 30, 2002Publication date: January 8, 2004Inventors: Marvin Martin Hansen, John Xiaoqiang He, Nicholas Allan Honigschmidt, Daniel James Koch, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
-
Patent number: 6673790Abstract: The present invention relates to novel indolin-2-one derivatives of formula: to the preparation and to the pharmaceutical compositions comprising them. These compounds have an affinity for oxytocin receptors.Type: GrantFiled: October 2, 2002Date of Patent: January 6, 2004Assignee: Sanofi-SynthelaboInventors: LoĂŻc Foulon, Georges Garcia, Claudine Serradeil-Le Gal, GĂ©rard Valette
-
Publication number: 20030236230Abstract: The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring.Type: ApplicationFiled: April 9, 2003Publication date: December 25, 2003Applicant: The Procter & Gamble CompanyInventors: Frank Hallock Ebetino, Xuewei Liu, Mark Gregory Solinsky, John August Wos
-
Publication number: 20030232828Abstract: The present invention provides compounds of formula I and the use thereof for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.Type: ApplicationFiled: June 3, 2003Publication date: December 18, 2003Applicant: WyethInventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler A. Antane, Ping Zhou, Yanfang Li
-
Publication number: 20030229069Abstract: The present invention provides a compound of the formula: 1Type: ApplicationFiled: June 4, 2003Publication date: December 11, 2003Applicant: Roche Palo Alto LLCInventors: Robin Douglas Clark, Shu-Hai Zhao
-
Publication number: 20030229075Abstract: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.Type: ApplicationFiled: March 28, 2003Publication date: December 11, 2003Inventors: Hui Cai, James P. Edwards, Steven P. Meduna, Barbara A. Pio, Jianmei Wei
-
Patent number: 6660736Abstract: This invention relates to phthalimido derivatives of the formula wherein X is —N═ or —CH═, and R1 to R4 and m are as defined in the specification, as well as their pharmaceutically acceptable salts. The invention further relates to pharmaceutical compositions containing these compounds, a method of treating a disease by administering a therapeutically effective amount of at least one of these compounds, and a process for their preparation for the treatment or prevention of diseases in which MAO-B inhibitors might be beneficial.Type: GrantFiled: March 13, 2003Date of Patent: December 9, 2003Assignee: Hoffmann-La Roche Inc.Inventors: Andrea Cesura, Rosa Maria Rodriguez Sarmiento, Andrew William Thomas, Rene Wyler
-
Publication number: 20030225060Abstract: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.Type: ApplicationFiled: February 3, 2003Publication date: December 4, 2003Inventors: Feroze Ujjainwalla, Lin Chu, Mark T. Goulet, Bonnie Louridas, Matthew J. Wyvratt, Daniel Warner
-
Publication number: 20030225090Abstract: The present invention is related to oxindole derivatives, compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.Type: ApplicationFiled: February 27, 2003Publication date: December 4, 2003Inventors: Philip Anthony Harris, Robert Walton McNutt, Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael Robert Peel, Edgar Raymond Wood
-
Publication number: 20030225121Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.Type: ApplicationFiled: May 20, 2003Publication date: December 4, 2003Applicant: WyethInventors: Ping Zhou, Michael Gerard Kelly, Yanfang Li
-
Publication number: 20030225281Abstract: The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.Type: ApplicationFiled: September 9, 2002Publication date: December 4, 2003Inventors: John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
-
Publication number: 20030225105Abstract: Compound of formula (I): 1Type: ApplicationFiled: February 20, 2003Publication date: December 4, 2003Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole VIlleneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Publication number: 20030224999Abstract: The invention is directed to novel indole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.Type: ApplicationFiled: March 31, 2003Publication date: December 4, 2003Inventors: Han-Cheng Zhang, William J. Hoekstra, Bruce E. Maryanoff, David F. McComsey
-
Publication number: 20030220319Abstract: This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: 1Type: ApplicationFiled: January 31, 2003Publication date: November 27, 2003Inventors: Robert Greenhouse, Saul Jaime-Figueroa, Lubica Raptova
-
Patent number: 6645980Abstract: One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.Type: GrantFiled: November 20, 2000Date of Patent: November 11, 2003Assignee: Sepracor Inc.Inventors: Gregory D. Cuny, Liming Shao, James R. Hauske, Michele L. R. Heffernan, Brian M. Aquila, Xinhe Wu, Fengjiang Wang, Thomas D. Bannister
-
Patent number: 6642232Abstract: The present invention relates to certain 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives that inhibit kinases, in particular VEGFR and/or PDGFR kinases. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.Type: GrantFiled: October 10, 2002Date of Patent: November 4, 2003Assignee: Sugen, Inc.Inventors: Matthew Mattson, Tomas Vojkovsky, Congxin Liang, Peng Cho Tang, Huiping Guan
-
Patent number: 6642251Abstract: The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Type: GrantFiled: January 15, 2003Date of Patent: November 4, 2003Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Todd Anthony Miller, Li Sun, Ngoc My Tran, Asaad Nematalla, Anh Thi Nguyen
-
Patent number: 6642256Abstract: Described are piperidines of Formula I and pharmaceutically acceptable salts thereof. The compounds of Formula I are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, pain, especially chronic pain, neuropathic pain, or surgical pain, or urinary incontinence.Type: GrantFiled: November 30, 2001Date of Patent: November 4, 2003Assignee: Warner-Lambert Company LLCInventors: Brian Edward Kornberg, Russell Andrew Lewthwaite, David Manning, Sham Shridhar Nikam, Ian Leslie Scott
-
Patent number: 6642228Abstract: There are provided compounds represented by the general formula (I): [wherein Ar is indole etc., R1 is hydrogen etc., B is bond, or B—N—R1 forms a ring structure and is piperidine etc., n is 0, 1, etc., A is trimethylene, butylene, etc., Q is piperidine, isoindoline, etc.], or pharmacologically acceptable acid addition salts thereof, and &agr;1B adrenoceptor antagonists composed of these substances. The invented compounds are antagonists having high affinity for &agr;1B adrenoceptor and are useful as pharmaceutical agents for use in prophylaxis/therapy of diseases (e.g., hypertension) in which &agr;1B adrenoceptor is involved or as pharmacological tools for elucidation of physiological activities mediated by &agr;1B adrenoceptor.Type: GrantFiled: April 13, 2001Date of Patent: November 4, 2003Assignee: Toray Industries, Inc.Inventors: Ryoji Hayashi, Eiji Ohmori, Masafumi Isogaya, Mitsuhiro Moriwaki, Hiroki Kumagai
-
Patent number: 6638950Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.Type: GrantFiled: June 20, 2001Date of Patent: October 28, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: John V. Duncia, Joseph B. Santella, Dean A. Wacker, Wenqing Yao, Changsheng Zheng
-
Publication number: 20030199689Abstract: The present invention relates to compounds of formula I, 1Type: ApplicationFiled: November 21, 2002Publication date: October 23, 2003Inventors: Marc Nazare, Melanie Essrich, David William Will, Hans Matter, Kurt Ritter, Volkmar Wehner
-
Publication number: 20030199553Abstract: A compound of the formula 1Type: ApplicationFiled: February 19, 2003Publication date: October 23, 2003Inventor: Ronald B. Gammill
-
Patent number: 6635640Abstract: The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.Type: GrantFiled: June 29, 2001Date of Patent: October 21, 2003Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Chung Chen Wei, Ping Huang, Jingrong Cui
-
Patent number: 6635771Abstract: Compounds of the formula in which R, R′, R7-R11, X, n1 and n3 are as defined herein. These compounds are useful as intermediates for preparing pharmaceutical compounds having pharmacological activity as chemical inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes.Type: GrantFiled: November 22, 2002Date of Patent: October 21, 2003Assignee: WyethInventors: John C. McKew, Steven Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark
-
Publication number: 20030195355Abstract: The invention is directed to methods to inhibit p38-&agr; kinase using compounds of the formula 1Type: ApplicationFiled: May 28, 2002Publication date: October 16, 2003Inventors: Babu J. Mavunkel, Sarvajit Chakravarty, John J. Perumattam, Sundeep Dugar, Qing Lu, Xi Liang
-
Publication number: 20030191133Abstract: The present invention relates to dopamine D4 ligands having the general formula I 1Type: ApplicationFiled: December 9, 2002Publication date: October 9, 2003Applicant: H. Lundbeck A/SInventors: Benny Bang-Andersen, Jakob Felding, Jan Kehler, Kim Andersen